Source: International Congress 2018 – Sarcoidosis: from basic research to patient outcomes
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Boyd (London, United Kingdom), R. Baughman (Cincinnati, United States of America), D. Valeyere (Paris, France), A. Álvarez Rodríguez (Santander, Spain), L. Charvoz (Lausanne, Switzerland), H. Faber (Meerbusch , Germany), C. Knoet (The Hague, Netherlands), F. Martone (Bologna, Italy), D. Novel (Yverdon-les-Bains, Switzerland), B. Quadder (Meerbusch, Germany), J. Richardson (London, United Kingdom), G. Spitzer (Chicago, United States of America), G. Ziosi (Bologna, Italy), J. Hochreiter (Neulengbach, Austria). Sarcoidosis treatment and outcomes: what is most important to patients?. 5219

Member's Comments

No comment yet.

Related content which might interest you: Sarcoidosis: patient treatment priorities Source: ERJ Open Res, 4 (4) 00141-2018; 10.1183/23120541.00141-2018 Year: 2018 Haemoptysis: aetiology, outcome and treatment Source: Eur Respir J 2006; 28: Suppl. 50, 9s Year: 2006 Adherence and effectiveness of omalizumab treatment in severe allergic asthma patients: Do the patients like injectable treatment? Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Dynapenia in COPD exacerbation: what is its relevance in clinical prognosis? Source: International Congress 2017 – Assessing functional outcomes in respiratory physiotherapy Year: 2017 Rare lung diseases in children: challenges for diagnosis and treatment Source: Virtual Congress 2021 – Rare lung diseases 2021 Year: 2021 Pulmonary rehabilitation: can we identify the patients who will benefit most? Source: Eur Respir J 2001; 18: Suppl. 33, 187s Year: 2001 Empyema in children: conservative treatment and immunologic status Source: Eur Respir J 2002; 20: Suppl. 38, 590s Year: 2002 Treatment burden is important to patients but often overlooked by clinicians Source: Breathe, 17 (1) 210031; 10.1183/20734735.0031-2021 Year: 2021 Readmission in COPD patients: should we consider it a marker of quality of care or a marker of a more severe disease with a worse prognosis? Source: Eur Respir J 2016; 48: 281-282 Year: 2016 Readmission in COPD patients: should we consider it a marker of quality of care or a marker of a more severe disease with a worse prognosis? Source: Eur Respir J 2016; 48: 279-281 Year: 2016 Tuberculosis in the elderly: clinical presentation and outcome Source: Annual Congress 2007 - Medical and surgical treatment of susceptible and resistant tuberculosis Year: 2007 Patients’ adherence to chronic treatment in lung diseases: Preliminary data from a randomized controlled trial Source: International Congress 2016 – Monitoring airway diseases with clinical tools Year: 2016 Combination therapy versus separate therapy in real-life primary care asthma patients Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care Year: 2015 Impact of community pharmacists‘ interventions on patients‘ asthma control and perception of therapy and disease: Results in patients with inadequate control at inclusion Source: Annual Congress 2010 - Therapy and health economics of asthma and COPD Year: 2010 Sarcoidosis in chilhood: Is it different from sarcoidosis in adults? Source: Eur Respir J 2003; 22: Suppl. 45, 505s Year: 2003 Which is the most effective inflammatory marker in the diagnosis, severity and treatment follow-up of patients with pneumonia? Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia Year: 2019